The EU Medical Device Regulation (MDR) has reshaped what “market access” means for medical device companies, and U.S. manufacturers are feeling that impact as sharply as anyone. While many U.S. firms have long been comfortable operating under FDA expectations, MDR’s emphasis on demonstrable clinical evidence, lifecycle surveillance, and stricter oversight by Notified Bodies has required new processes, new documentation discipline, and often new timelines. Progress is real, but uneven—driven by product risk class, legacy portfolio complexity, and how quickly teams can convert “we comply” into “we can prove it.”

MDR Readiness: Where U.S. Manufacturers Stand Now

U.S. companies that were early movers on MDR readiness typically share one trait: they treated MDR as a business continuity program, not a regulatory paperwork exercise. Those organizations started with portfolio triage—identifying high-revenue or strategically critical devices, mapping them to MDR classification rules, and assessing whether an existing CE certificate could realistically be transitioned before expiration. In many cases, firms have narrowed initial MDR scope to protect core products first, delaying lower-margin SKUs or pruning the long tail of legacy devices that are costly to remediate.

A common pattern is that U.S. manufacturers are strongest where MDR overlaps with established FDA habits: quality systems rigor, complaint handling, and basic risk management. Many already had mature ISO 13485 frameworks and can adapt to MDR expectations around design controls, CAPA, and supplier management. Readiness drops, however, when MDR requires deeper EU-specific demonstration—particularly around Clinical Evaluation Reports (CERs) aligned to MDR and MEDDEV guidance, updated risk-benefit justifications, and more explicit traceability from claims to evidence to labeling.

Notified Body access remains one of the defining readiness constraints. Even well-prepared U.S. firms report bottlenecks: long queues for MDR certification slots, limited reviewer bandwidth, and iterative questions that extend review cycles. As a result, “readiness” increasingly means having a defensible submission package early enough to survive multiple rounds of review without missing certificate deadlines. Companies progressing fastest often have dedicated EU regulatory leadership, early engagement meetings with Notified Bodies, and a centralized document strategy that reduces back-and-forth.

Closing Compliance Gaps: Strategy, Evidence, Timelines

The most persistent MDR compliance gaps for U.S. manufacturers tend to center on clinical evidence and post-market obligations. Many legacy devices were supported by equivalence arguments that are now harder to sustain under MDR, pushing firms toward stronger clinical evaluation methodology, better access to clinical data, and—where necessary—new clinical investigations. At the same time, MDR’s post-market surveillance expectations (including PMCF plans and reports, PSURs for higher-risk classes, and trending) require operational muscle: defined signals, thresholds, responsibilities, and reporting rhythms that can be audited.

Successful strategies usually start with a structured gap assessment and a risk-based remediation roadmap. Companies break the work into concrete deliverables—GSPR checklists, updated risk management files, CER updates, PMS/PMCF documentation, UDI and labeling changes, and technical documentation restructuring—then align owners and timelines across regulatory, clinical, quality, and engineering. Many U.S. organizations also invest in evidence traceability tools or stronger document control to ensure every claim in marketing, IFU, and labeling can be linked to verified standards testing, clinical literature, usability validation, or real-world performance data.

Timelines are where U.S. companies are learning to recalibrate expectations. Under MDR, planning backward from certificate expiry is often insufficient; firms need buffers for Notified Body availability, possible remediation cycles, and additional testing or clinical work triggered by reviewer questions. Leaders are building multi-scenario plans (best case, expected case, and “review expands” case), reserving internal capacity for rapid responses, and using portfolio staging—submitting prioritized device families first to maintain EU revenue while subsequent waves follow. In parallel, many companies are strengthening EU Authorized Representative relationships and internal vigilance processes so post-market requirements are not treated as a “post-approval” afterthought.

U.S. companies are progressing under the EU MDR, but the trajectory depends on how quickly they can shift from legacy CE maintenance to MDR-grade proof—especially for clinical evidence and lifecycle surveillance. The manufacturers pulling ahead are the ones treating MDR as a cross-functional transformation with real resourcing, clear portfolio decisions, early Notified Body engagement, and disciplined evidence traceability. For everyone else, the path forward is still achievable—but it demands candid gap identification, pragmatic prioritization, and timelines built for the reality of MDR review cycles rather than the optimism of past regimes.